comparemela.com
Home
Live Updates
Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA : comparemela.com
Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA
At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.
Related Keywords
Robert Wessman ,
Momna Ali ,
Cameroni Alvotech ,
,
Rheumatology Informatics System ,
Clinical Disease Activity Index ,
Disease Activity ,
Rheumatoid Arthritis ,
Globenewswire News ,
comparemela.com © 2020. All Rights Reserved.